依巴斯汀三倍剂量治疗轻中度特应性皮炎的疗效和安全性
|
摘要
目的:评价依巴斯汀三倍剂量治疗特应性皮炎的有效性和安全性。方法:选取轻度至中度的特应性皮炎患者为研究对象,随机分为观察组和对照组。观察组口服依巴斯汀片30 mg/d联合医用凡士林外用,对照组口服依巴斯汀片10 mg/d联合医用凡士林外用,观察两组患者在28天治疗后的瘙痒评分、SCORAD总分、临床总有效率以及发生的不良反应。结果:共收集患者128例,其中观察组和对照组各64例,观察组的瘙痒评分、SCORAD总分分别为3.02±1.19和21.83±3.05均显著低于对照组的6.77±1.33和29.28±4.91(P<0.05);观察组临床总有效率为93.33%高于对照组的68.75%,差异有统计学意义(P<0.05);观察组不良反应发生率为6.3%,对照组为9.4%,两组不良反应比较无统计学差异(P>0.05)。结论:与常规剂量的依巴斯汀比较,30 mg/d的依巴斯汀治疗特应性皮炎疗效优于10 mg/d,不良反应无明显差异。
Objective: To evaluate the efficacy and safety of three-times the dose of Ebastine in the treatment of the patients with atopic dermatitis(AD). Methods: The patients with mild to moderate AD were collected and were divided into the observation group and the control group randomly. The patients in the observation group were treated with Ebastine 30 mg/d,orally and topical Vaseline and those in the control group was treated with Ebastine 10 mg/d, orally and topical Vaseline. After 28 days of the treatment, the itching score, SCORAD score, total clinical efficacy rate and adverse reaction were assessed. Results: A total of 128 patients were collected(64 patients in each group). The itching score and SCORAD in the observation group were 3.02±1.19 and 21.83±3.05, which were lower than those in the control group(6.77±1.33 and 29.28±4.91), with significant differences(P<0.05). The efficacy in the observation group was 93.33%, which was higher than that in the control group(68.75%), with a significant difference(P<0.05). The adverse reaction rate in the observation group and control group were 6.3% and 9.4% respectively, with no significant difference(P>0.05). Conclusion: 30 mg/d Ebastine in the treatment of atopic dermatitis is more effective than 10 mg/d, with similar adverse reaction.
Objective: To evaluate the efficacy and safety of three-times the dose of Ebastine in the treatment of the patients with atopic dermatitis(AD). Methods: The patients with mild to moderate AD were collected and were divided into the observation group and the control group randomly. The patients in the observation group were treated with Ebastine 30 mg/d,orally and topical Vaseline and those in the control group was treated with Ebastine 10 mg/d, orally and topical Vaseline. After 28 days of the treatment, the itching score, SCORAD score, total clinical efficacy rate and adverse reaction were assessed. Results: A total of 128 patients were collected(64 patients in each group). The itching score and SCORAD in the observation group were 3.02±1.19 and 21.83±3.05, which were lower than those in the control group(6.77±1.33 and 29.28±4.91), with significant differences(P<0.05). The efficacy in the observation group was 93.33%, which was higher than that in the control group(68.75%), with a significant difference(P<0.05). The adverse reaction rate in the observation group and control group were 6.3% and 9.4% respectively, with no significant difference(P>0.05). Conclusion: 30 mg/d Ebastine in the treatment of atopic dermatitis is more effective than 10 mg/d, with similar adverse reaction.
引文
[1] Liu P, Zhao Y, Mu ZL, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis[J].中华医学杂志(英文版),2016,129(7):757-762.
[2] 赵辨.临床皮肤病学[M].南京:江苏科学技术出版社,2009:739.
[3] 王珊,马琳. 特应性皮炎严重程度的评估[J]. 中国医学文摘(皮肤科学), 2016,33(2):154-159.
[4] 中华医学会皮肤性病学分会免疫学组.中国特应性皮炎诊疗指南(2014年版)[J]. 全科医学临床与教育,2014,47(6):603-606.
[5] Katayama I, Kohno Y, Akiyama K, et al. Japanese guideline for atopic dermatitis 2014[J]. Allergol Int,2014,63(3):377-398.
[6] 孙彩虹,顾恒. 特应性皮炎的流行病学特征[J]. 中国医学文摘(皮肤科学), 2016,33(2):101-106.
[7] Bell DC, Brown SJ. Atopic eczema treatment now and in the future:Targeting the skin barrier and key immune mechanisms in human skin[J]. World J Dermatol,2017,6(3):42-51.
[8] 李建红, 李萍, 刘建中, 等. 特应性皮炎外周血白介素17水平检测[J]. 中国麻风皮肤病杂志,2009,25(10):742-743.
[9] Incorvaria C, Frati F, Verna N, et al. Allergy and the skin[J]. Clin Exp Immunol,2008,153:27-29.
[10] Mu ZL, Zhao Y, Liu XJ, et al. Molecular Biology of Atopic Dermatitis[J]. Clin Rev Allergy Immunol,2014,47(2):193-218.
[11] Malloy CA, Yousef E. Determination of severity of atopic dermatitis: role of eosinophilic cationic protein (ECP)[J]. J Allergy Clin Immunol,2008,123(2):s39.
[12] 薛慧,李军娜,张焕珍,等. 398例特应性皮炎患儿血清IgE检测结果分析[J]. 中国药物与临床,2016,16(9):1315-1317.
[13] 徐倩玥, 余红. 嗜酸性粒细胞在特应性皮炎发病中的作用与机制[J]. 临床儿科杂志,2017,35(5):389-393.
[14] 尹晓慧.依巴斯汀治疗慢性荨麻疹疗效观察[J].中国麻风皮肤病杂志,2005,21(12):1005.
[15] 陈绍谦,蔡川川,郑明振.依巴斯汀和左西替利嗪治疗慢性特发性荨麻疹的临床对照研究[J].中国麻风皮肤病杂志,2006,22(1):47-49.
[2] 赵辨.临床皮肤病学[M].南京:江苏科学技术出版社,2009:739.
[3] 王珊,马琳. 特应性皮炎严重程度的评估[J]. 中国医学文摘(皮肤科学), 2016,33(2):154-159.
[4] 中华医学会皮肤性病学分会免疫学组.中国特应性皮炎诊疗指南(2014年版)[J]. 全科医学临床与教育,2014,47(6):603-606.
[5] Katayama I, Kohno Y, Akiyama K, et al. Japanese guideline for atopic dermatitis 2014[J]. Allergol Int,2014,63(3):377-398.
[6] 孙彩虹,顾恒. 特应性皮炎的流行病学特征[J]. 中国医学文摘(皮肤科学), 2016,33(2):101-106.
[7] Bell DC, Brown SJ. Atopic eczema treatment now and in the future:Targeting the skin barrier and key immune mechanisms in human skin[J]. World J Dermatol,2017,6(3):42-51.
[8] 李建红, 李萍, 刘建中, 等. 特应性皮炎外周血白介素17水平检测[J]. 中国麻风皮肤病杂志,2009,25(10):742-743.
[9] Incorvaria C, Frati F, Verna N, et al. Allergy and the skin[J]. Clin Exp Immunol,2008,153:27-29.
[10] Mu ZL, Zhao Y, Liu XJ, et al. Molecular Biology of Atopic Dermatitis[J]. Clin Rev Allergy Immunol,2014,47(2):193-218.
[11] Malloy CA, Yousef E. Determination of severity of atopic dermatitis: role of eosinophilic cationic protein (ECP)[J]. J Allergy Clin Immunol,2008,123(2):s39.
[12] 薛慧,李军娜,张焕珍,等. 398例特应性皮炎患儿血清IgE检测结果分析[J]. 中国药物与临床,2016,16(9):1315-1317.
[13] 徐倩玥, 余红. 嗜酸性粒细胞在特应性皮炎发病中的作用与机制[J]. 临床儿科杂志,2017,35(5):389-393.
[14] 尹晓慧.依巴斯汀治疗慢性荨麻疹疗效观察[J].中国麻风皮肤病杂志,2005,21(12):1005.
[15] 陈绍谦,蔡川川,郑明振.依巴斯汀和左西替利嗪治疗慢性特发性荨麻疹的临床对照研究[J].中国麻风皮肤病杂志,2006,22(1):47-49.